Department of Orthopaedics, YongKangShi Hospital of Traditional Chinese Medicine, Yongkang.
Department of Orthopaedics, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, P.R. China.
Medicine (Baltimore). 2021 Apr 9;100(14):e24118. doi: 10.1097/MD.0000000000024118.
Genetic alterations are vital to the progression of osteosarcoma carcinoma. The present study investigated a panel of gene signatures that could evaluate prognosis in osteosarcoma based on data from the Therapeutically Applicable Research To Generate Effective Treatments initiative. Osteosarcoma messenger RNA (mRNA) profiles and clinical data were downloaded from the therapeutically applicable research to generate effective treatments database. Patients with osteosarcoma were divided into two groups based on findings at diagnosis: with and without metastasis. Differentially expressed mRNAs were compared and analyzed between groups. Univariate and multivariate Cox regression analyses identified a set of eight mRNAs with the ability to classify patients into high-risk and low-risk groups with significantly different overall survival times. Further analysis indicated that the eight-mRNA signature was an independent prognostic factor after adjusting for other clinical factors. Receiver operating characteristic curve analysis demonstrated a good performance of the eight-mRNA signature. Further, the biological processes and signaling pathways of the eight-mRNA signature were reviewed using Gene Ontology and Kyoto Encyclopedia of Genes and Genomes resources. Finally, the results of the TCGA analysis were verified by other cohorts from Gene Expression Omnibus database. The identification of an eight-mRNA signature not only provides a prognostic biomarker of osteosarcoma but also offers the potential of novel therapeutic targets for its treatment.
遗传改变对于骨肉瘤的进展至关重要。本研究基于治疗性应用研究以产生有效治疗倡议的数据,调查了一组基因特征,这些特征可用于评估骨肉瘤的预后。从治疗性应用研究以产生有效治疗数据库中下载骨肉瘤信使 RNA(mRNA)谱和临床数据。根据诊断时的发现将骨肉瘤患者分为两组:有转移和无转移。比较并分析组间差异表达的 mRNA。单变量和多变量 Cox 回归分析确定了一组 8 个能够将患者分为总生存时间明显不同的高风险和低风险组的 mRNA。进一步分析表明,在调整其他临床因素后,该 8-mRNA 特征是独立的预后因素。接收器操作特性曲线分析表明该 8-mRNA 特征具有良好的性能。此外,还使用基因本体论和京都基因与基因组百科全书资源对 8-mRNA 特征的生物学过程和信号通路进行了回顾。最后,通过来自基因表达综合数据库的其他队列验证了 TCGA 分析的结果。该 8-mRNA 特征的鉴定不仅提供了骨肉瘤的预后生物标志物,而且为其治疗提供了新的治疗靶点的潜力。